skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Estrogenic compounds inhibit gap junctional intercellular communication in mouse Leydig TM3 cells

Journal Article · · Toxicology and Applied Pharmacology
 [1];  [2];  [3]
  1. Department of Bioenvironmental Medicine, Graduate School of Medicine, Chiba University, Chiba 260-8670 (Japan) and Toxicology Laboratory, Pharmaceuticals Research Unit, Research and Development Division, Mitsubishi Pharma Corporation, Kisarazu 292-0818 (Japan) and Environmental Health Science Project for Future Generations, Graduate School of Medicine, Chiba University, Chiba 260-8670 (Japan)
  2. Department of Bioenvironmental Medicine, Graduate School of Medicine, Chiba University, Chiba 260-8670 (Japan) and Environmental Health Science Project for Future Generations, Graduate School of Medicine, Chiba University, Chiba 260-8670 (Japan)
  3. Department of Bioenvironmental Medicine, Graduate School of Medicine, Chiba University, Chiba 260-8670 (Japan) and Environmental Health Science Project for Future Generations, Graduate School of Medicine, Chiba University, Chiba 260-8670 (Japan) and Center for Environment, Health and Field Sciences, Chiba University, Kashiwa 277-0882 (Japan)

Some estrogenic compounds are reported to cause testicular disorders in humans and/or experimental animals by direct action on Leydig cells. In carcinogenesis and normal development, gap junctional intercellular communication (GJIC) plays an essential role in maintaining homeostasis. In this study, we examine the effects of diethylstilbestrol (DES, a synthetic estrogen), 17{beta}-estradiol (E{sub 2}, a natural estrogen), and genistein (GEN, a phytoestrogen) on GJIC between mouse Leydig TM3 cells using Lucifer yellow microinjection. The three compounds tested produced GJIC inhibition in the TM3 cells after 24 h. Gradually, 10 {mu}M DES began to inhibit GJIC for 24 h and this effect was observed until 72 h. On the other hand, both 20 {mu}M E{sub 2} and 25 {mu}M GEN rapidly inhibited GJIC in 6 h and 2 h, respectively. The effects continued until 24 h, but weakened by 72 h. Furthermore, a combined effect at {mu}M level between DES and E{sub 2} on GJIC inhibition was observed, but not between GEN and E{sub 2}. DES and E{sub 2} showed GJIC inhibition at low dose levels (nearly physiological estrogen levels) after 72 h, but GEN did not. DES-induced GJIC inhibition at 10 pM and 10 {mu}M was completely counteracted by ICI 182,780 (ICl), an estrogen receptor antagonist. On the other hand, the inhibitory effects on GJIC with E{sub 2} (10 pM and 20 {mu}M) and GEN (25 {mu}M) were partially blocked by ICI or calphostin C, a protein kinase C (PKC) inhibitor, and were completely blocked by the combination of ICI and calphostin C. These results demonstrate that DES inhibits GJIC between Leydig cells via the estrogen receptor (ER), and that E{sub 2} and GEN inhibit GJIC via ER and PKC. These estrogenic compounds may have different individual nongenotoxic mechanism including PKC pathway on testicular carcinogenesis or development.

OSTI ID:
20783470
Journal Information:
Toxicology and Applied Pharmacology, Vol. 212, Issue 3; Other Information: DOI: 10.1016/j.taap.2005.08.005; PII: S0041-008X(05)00510-7; Copyright (c) 2005 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0041-008X
Country of Publication:
United States
Language:
English